Bristol-Myers Squibb Co (BMY) saw a price increase of 3.01%, reaching a 20-day high, despite the Nasdaq-100 and S&P 500 experiencing declines of 0.51% and 0.24%, respectively.
This surge is attributed to the FDA granting priority review for Bristol-Myers Squibb's Opdivo for Hodgkin lymphoma, marking a significant milestone in treatment options for patients. The acceptance of the supplemental Biologics License Application is based on promising clinical trial data, which indicates the potential for improved patient outcomes and solidifies the company's position in oncology.
The FDA's decision is expected to enhance investor confidence and may lead to increased market interest in Bristol-Myers Squibb's innovative therapies, particularly as the company continues to advance its pipeline in oncology and immunotherapy.
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 55.560
Low
37.00
Averages
55.86
High
68.00
Current: 55.560
Low
37.00
Averages
55.86
High
68.00
Piper Sandler
Overweight
maintain
$62 -> $66
2026-01-28
New
Reason
Piper Sandler
Price Target
$62 -> $66
AI Analysis
2026-01-28
New
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Bristol Myers to $66 from $62 and keeps an Overweight rating on the shares. The firm says Bristol continues to profile as inexpensive, with the shares essentially pricing in the eventual Eliquis U.S. LOE, but not adequately reflecting what in Piper's view is growing visibility into a return to growth on the back of steady pipeline advancement.
Citi
Geoff Meacham
Neutral
maintain
$53 -> $60
2026-01-27
New
Reason
Citi
Geoff Meacham
Price Target
$53 -> $60
2026-01-27
New
maintain
Neutral
Reason
Citi analyst Geoff Meacham raised the firm's price target on Bristol Myers to $60 from $53 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are "beatable" and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMY
Unlock Now
Scotiabank
Louise Chen
Sector Perform
maintain
$53 -> $60
2026-01-09
Reason
Scotiabank
Louise Chen
Price Target
$53 -> $60
2026-01-09
maintain
Sector Perform
Reason
Scotiabank analyst Louise Chen raised the firm's price target on Bristol Myers to $60 from $53 and keeps a Sector Perform rating on the shares. The firm believes the upcoming year is "catalyst-rich" and its inexpensive valuation makes the stock appear attractive, the analyst tells investors.
UBS
Neutral -> Buy
upgrade
$46 -> $65
2026-01-07
Reason
UBS
Price Target
$46 -> $65
2026-01-07
upgrade
Neutral -> Buy
Reason
UBS upgraded Bristol Myers to Buy from Neutral with a price target of $65, up from $46, after assuming coverage of the name. After several challenging years, biotech and pharma are emerging from a cyclical trough, supported by improving macro conditions, stronger fundamentals, increased FDA approvals, positive clinical data, and accelerating M&A, the analyst says in a research note. Investor confidence is expected to rise in 2026, setting the stage for sector outperformance, UBS adds.
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
